Burden of illness: direct and indirect costs among persons with hemophilia A in the United States
- 9 February 2015
- journal article
- Published by Informa Healthcare in Journal of Medical Economics
- Vol. 18 (6), 457-465
- https://doi.org/10.3111/13696998.2015.1016228
Abstract
To examine the direct and indirect costs of hemophilia care among persons with hemophilia A in the US.Observational data were obtained from HUGS-Va, a multi-center study from six federally supported hemophilia treatment centers (HTCs). Eligible individuals completed a standardized initial questionnaire and were followed regularly for 2 years to obtain information on work or school absenteeism, time spent arranging hemophilia care, and unpaid hemophilia-related support from caregivers. Data from 1-year healthcare utilization records and 2-year clotting factor dispensing records measured direct medical costs. Indirect costs were imputed using the human capital approach, which uses wages as a proxy measure of work time output.A total of 222 patients with complete data were included in the analysis. Two-thirds had severe hemophilia and the mean age was 21.1 years. The use of prophylaxis in severe hemophilia patients is associated with statistically significant reduction in the numbers of emergency department (ED) visits and bleeding episodes compared with those who were treated episodically. From the societal perspective, mild hemophilia costs $59,101 (median: $7519) annually per person, $84,363 (median: $61,837) for moderate hemophilia, $201,471 (median: $143,431) for severe hemophilia using episodic treatment, and $301,392 (median: $286,198) for severe hemophilia receiving prophylaxis. Clotting factor contributed from 54% of total costs in mild hemophilia to a maximum of 94% for patients with severe hemophilia receiving prophylaxis.Hemophilia is a costly disorder not only because of its high medical expenses, but also due to the high indirect costs incurred.Keywords
This publication has 18 references indexed in Scilit:
- Healthcare resource utilization among haemophilia A patients in the United StatesHaemophilia, 2011
- A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)Journal of Thrombosis and Haemostasis, 2011
- Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practiceBritish Journal of Clinical Pharmacology, 2010
- High School Completion Rates Among Men with HemophiliaAmerican Journal of Preventive Medicine, 2010
- Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe HemophiliaNew England Journal of Medicine, 2007
- Costs of on‐demand and prophylactic treatment for severe haemophilia in Norway and SwedenHaemophilia, 2004
- Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factorsBlood, 2004
- Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study GroupBlood, 2003
- Quality‐of‐life differences between prophylactic and on‐demand factor replacement therapy in European haemophilia patientsHaemophilia, 2002
- Home‐based factor infusion therapy and hospitalization for bleeding complications among males with haemophiliaHaemophilia, 2001